China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 99.0% in February

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 74,183 shares, a drop of 99.0% from the January 29th total of 7,347,822 shares. Currently, 8.0% of the company’s stock are short sold. Based on an average trading volume of 1,094,984 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 1,094,984 shares, the days-to-cover ratio is presently 0.1 days. Currently, 8.0% of the company’s stock are short sold.

China SXT Pharmaceuticals Price Performance

Shares of SXTC stock traded down $0.01 during trading hours on Wednesday, hitting $2.25. The stock had a trading volume of 39,845 shares, compared to its average volume of 643,834. The stock’s 50 day moving average is $81.40 and its 200 day moving average is $175.87. China SXT Pharmaceuticals has a twelve month low of $1.96 and a twelve month high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings data on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SXTC. Virtu Financial LLC lifted its position in China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares during the period. Citadel Advisors LLC acquired a new stake in China SXT Pharmaceuticals in the third quarter valued at $78,000. Finally, XTX Topco Ltd acquired a new position in shares of China SXT Pharmaceuticals during the 4th quarter worth $36,000. 5.02% of the stock is currently owned by institutional investors and hedge funds.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.